Politician suffers stroke on live TV and rushed to hospital
The former minister for public investment appeared on a morning show for the Serbian television channel Pink on Tuesday (August 5). But things took a chilling turn when the dad-of-two's demeanor changed halfway through the televised interview.
The politician's speech began to slow down and his eyes slowly started to close as he attempted to still speak to the hosts of the show. The clip went viral on social media after being reposted by European outlet Nexta.
Thousands of viewers watched it in disbelief as his speech slurred and one side of his began to droop, both of which are common signs of a stroke, according to the NHS.
The minister was then rushed to hospital at the Clinical Centre of Serbia and believed to be in a "very serious condition", according to Serbian newspaper, Informer.
The outlet went on to claim that he was hospitalised in "an unconscious state" adding that "doctors are now fighting for his life". Zlatibor Lončar, another Serbian politician, has revealed that the minister had an "extremely complex operation" which "took longer than expected".
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
6 minutes ago
- Daily Record
Three new cancer drugs approved for use for NHS Scotland
The drugs have been approved for use by the NHS in Scotland. Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Ex-gangster Ian 'Blink' MacDonald turns back on underworld after pals all die from drugs and shootings Dad of schoolgirl slain in Dunblane massacre warns gun licensing reform does not go far enough Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. NHS Scotland. ' Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.'
The Herald Scotland
16 minutes ago
- The Herald Scotland
Three new cancer drugs approved for use for NHS Scotland
However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. READ MORE: The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Mr Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.'
Daily Record
3 hours ago
- Daily Record
Nearly 2,000 patient falls recorded in Dumfries and Galloway during course of 2024
The number of falls recorded has risen by more than a third in the past five years. Nearly 2,000 patient falls were recorded in Dumfries and Galloway last year. And the number of falls recorded has risen by more than a third in the space of five years. The figures were revealed following a series of freedom of information requests by Scottish Labour. South Scotland Labour MSP Colin Smyth said: 'Falls can be life-changing for older and more vulnerable patients. 'Figures in Dumfries and Galloway have increased by a third since 2019, which is shocking. 'With long queues at accident and emergency and out-of-date hospitals, hard-working NHS staff are already stretched to breaking point. 'The SNP must act now to ensure that patients don't come to unnecessary harm because of the condition of the estate or overcrowding.' NHS Dumfries and Galloway was one of nine health boards which saw a rise in patient falls between 2019 and 2024. There were 1,976 recorded falls in 2024, compared to 1,478 in 2019 – an increase of 34 per cent. There have already been 704 falls recorded in 2025. Across Scotland, there were 282,385 falls in 2024 – which represented a five per cent increase on the 2019 tally of 43,358. An NHS Dumfries and Galloway spokesman said: 'An increase in falls is an indicator of increased frailty –- and we have seen the numbers of people coming into hospital with underlying frailty increase over recent years. 'This is reflective of an older population, and can be an indicator of a general health decline among these populations within our communities. 'Work takes place to address movement of people while in hospital, noting the potential for rapid deconditioning – with muscle mass lost for every day someone spends in a chair or in bed. 'Teams need to balance the risk of increased deconditioning by maintaining mobility against the risk of falls while someone is in hospital. 'A falls risk assessment and management plan is completed for those identified as being at risk of falling, and we have worked with boards across Scotland to improve patient safety and reduce risk, with programmes in place to maintain mobility. 'There is also work aimed at preventing people from coming into hospital, which is a major focus of our Home Teams and Hospital at Home work. 'This reflects the fact that hospitals are clinical settings and not always the safest place for frail, older people who are already identified as vulnerable. 'A key objective amid our ongoing work is to ensure that people who no longer have a medical need to remain in hospital return safely home or to a homely setting as quickly as possible.' A Scottish Government spokesperson said: 'Patient safety is paramount and Scottish Ministers are committed to ensuring all health and care is safe, effective and patient-centred.'In 2025-26, NHS boards received increased investment in their baseline funding, bringing total investment to over £16.2 billion.'And the Scottish Government's Budget is providing more than £1 billion in capital investment, with £140 million additional funding targeted at high risk areas of maintenance and repair of the existing estate, equipment and digital replacement.'
